創傷生技藥品市場 - 全球與區域分析：按產品、地區、國家分析、競爭格局：分析與預測（2023-2030）

2022年全球創傷生技藥品市場規模為18.514億美元。

預計到2030年終，該市場將成長至 33.215 億美元，2023年至2030年年複合成長率為 7.71%。由於創傷和燒傷治療的需求不斷增加，創傷生技藥品市場經歷這種成長。該成長的促進因素包括燒傷發生率上升、糖尿病足潰瘍和壓瘡盛行率不斷上升，以及政府主導的目的是加強創傷護理的措施。

創傷生技藥品是源自人體細胞、組織和天然物質等生物資源的先進醫療材料。這些產品專門用於促進各種類型創傷患者的創傷治療和組織再生，包括糖尿病性潰瘍、褥瘡和靜脈潰瘍等慢性創傷，以及受傷和手術造成的急性創傷。創傷生技藥品包括生長因子、細胞外基質、細胞療法和生物工程皮膚替代，所有這些都與人體的自然癒合過程相互作用，以更佳促進創傷縫合和組織修復。最近的市場發展包括 BioTissue 於2023年 3月完成了佛羅裡達州多拉爾的設施擴建和維修。

本報告研究了全球創傷生技藥品市場，並提供了市場概述，包括依產品和地區分類的趨勢以及參與市場的公司概況。

目錄

執行摘要

第1章 市場

• 產品定義
• 納入與排除標準
• 關鍵問題的答案
• 分析與預測筆記
• 主要發現

第2章 產品

• 產品細分
• 產品概要
• 全球創傷生技藥品市場（依產品類型）

第3章 區域

• 區域概況
• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 其他地區

第4章 市場－競爭基準化分析

• 主要策略及發展
• 主要企業生態系統

第5章 調查方法

Global Wound Biologics Market Industry Overview

The global wound biologics market was valued at $1,851.4 million in 2022 and is anticipated to grow to $3,321.5 million by the end of 2030. This market is expected to expand at a compound annual growth rate (CAGR) of 7.71% between 2023 and 2030. Such growth is being experienced by the wound biologics market, owing to increasing demand for treating wounds and burn injuries. Drivers of this growth include the rising incidence of burn injuries, the expanding prevalence of diabetic foot ulcers and pressure ulcers, and government-led initiatives aimed at enhancing wound care treatments.

Market Introduction

Wound biologics products are advanced medical materials derived from biological sources such as human cells, tissues, or natural substances. These products are specifically designed to facilitate wound healing and tissue regeneration in patients with various types of wounds, including chronic wounds such as diabetic ulcers, pressure ulcers, and venous ulcers, as well as acute wounds from injuries or surgeries. Wound biologics can include growth factors, extracellular matrices, cellular therapies, and bioengineered skin substitutes, all aimed at promoting the natural healing processes of the body to achieve better wound closure and tissue repair. One recent development that has taken place in the market was in March 2023 when BioTissue completed a facility expansion and renovation in Doral, Florida, to support the growing demand and future expansion of its biologics product portfolio.

Market Segmentation:

Segmentation 1: by Product

• Growth Factors
• Skin Substitutes
• Topical Agents

Skin Substitutes to Lead the Global Wound Biologics Market (by Product)

Based on product, the wound biologics market is led by skin substitutes, which held a 63.78% share in 2022.

Segmentation 2: by Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Russian Federation
  • Turkey
  • Poland
  • Belgium
  • Sweden
  • Ireland
  • Norway
  • Austria
  • Denmark
  • Finland
  • Portugal
  • Czech Republic
  • Romania
  • Greece
  • Slovakia
  • Ukraine
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Malaysia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Colombia
  • Argentina
  • Chile
• Rest-of-the-World

Regionally, North America maintains a dominant position, and it is expected to grow through a steady compound annual growth rate (CAGR) of 6.66% from 2023 to 2030. This sustained growth can be attributed to the region's advanced healthcare infrastructure, widespread awareness of wound management, and a notable increase in chronic wounds among its aging populace.

The emphasis on R&D in North America has also facilitated the emergence of innovative wound biologics products, supported by a strong regulatory environment and healthcare policies favouring advanced wound care solutions. The emphasis on R&D in North America has also facilitated the emergence of innovative wound biologics, supported by a strong regulatory environment and healthcare policies favouring advanced wound care solutions.

Asia-Pacific and the Rest-of-the-World regions are projected to experience the highest growth rates, with CAGRs of 11.49% and 11.29%, respectively, indicating a rapidly expanding market presence. The growth in these regions is likely driven by improving healthcare infrastructure, rising awareness of effective wound care, and increasing accessibility to advanced medical treatments. Overall, the wound biologics market globally has been characterized by regional growth patterns influenced by healthcare advancements, demographic shifts, and a collective focus on improving wound care outcomes.

Recent Developments in the Wound Biologics Market

• In May 2023, Cellularity disclosed a significant purchase order amounting to $45 million in accordance with the first private label agreement in the Middle East for Cellularity Inc.'s halal-certified biomaterial products. The products, namely Biovance, Biovance 3L, Interfyl, and CentaFlex have obtained halal certification.
• In January 2022, Gunze Limited announced the commencement of Epiflex sales by Gunze Medical Limited, marking the first and only approved product available in Japan. It is important to note that Epiflex is a registered trademark of MiMedx Group, Inc.

How can this Report add value to an Organization?

Product/Innovation Strategy: The report can highlight current market gaps and emerging patient needs, guiding companies in developing new products or enhancing existing offerings.

Growth/Marketing Strategy: Regional analysis offers insights into market size, growth rates, and competitive landscapes across different territories, assisting in strategic planning for geographic expansion or consolidation.

Competitive Strategy: Understanding future market trends and growth forecasts allows companies to anticipate changes in the competitive landscape, adjust their strategies accordingly, and identify early opportunities for innovation and expansion.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2022. A historical year analysis has been done for the period FY2019-FY2021. The market size has been estimated for FY2022 and projected for the period FY2023-FY2030
• The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of upstream and downstream products of wound biologics.
• The market contribution of wound biologics products anticipated to be launched in the future has been calculated based on the historical analysis of the solutions.
• Revenues of the companies have been referenced from their annual reports for FY2022 and FY2023. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
• The market has been mapped based on the available wound biologics solutions. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in wound biologics, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and salespersons have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding the competitive landscape and business model
• Current and proposed production values of a product by market players
• Percentage split of individual markets for regional analysis

Secondary Research:

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• Segmentations and percentage shares
• Data for market value
• Key industry trends of the top players of the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The global competitive landscape of the wound biologics market is defined by the presence of several key players, each contributing to the market's growth through innovation, business expansion, funding, strategic partnerships, and a focus on expanding product portfolios. Leading companies in this space are distinguished by their commitment to research and development, which enables them to introduce advanced wound care solutions that address a range of needs, from basic wound protection to complex wound management scenarios.

Some prominent names established in this market are:

• AlloSource
• LifeNet Health
• Smith & Nephew plc.
• Sanara MedTech Inc.
• Mtf Biologics
• Becton, Dickinson and Company
• MiMedx Group, Inc.
• TissueTech, Inc.

Table of Contents

Executive Summary

1 Markets

• 1.1 Product Definition
• 1.2 Inclusion and Exclusion Criteria
  • 1.2.1 Inclusion
  • 1.2.2 Exclusion Criteria
• 1.3 Key Questions Answered
• 1.4 Analysis and Forecast Note
• 1.5 Key Findings

2 Products

• 2.1 Product Segmentation
• 2.2 Product Summary
• 2.3 Global Wound Biologics Market (by Product Type)
  • 2.3.1 Growth Factors
  • 2.3.2 Skin Substitutes
  • 2.3.3 Topical Agents

3 Regions

• 3.1 Regional Summary
• 3.2 North America
  • 3.2.1 U.S.
  • 3.2.2 Canada
• 3.3 Latin America
  • 3.3.1 Argentina
  • 3.3.2 Brazil
  • 3.3.3 Chile
  • 3.3.4 Colombia
  • 3.3.5 Mexico
• 3.4 Europe
  • 3.4.1 France
  • 3.4.2 U.K.
  • 3.4.3 Spain
  • 3.4.4 Italy
  • 3.4.5 Portugal
  • 3.4.6 Netherlands
  • 3.4.7 Ireland
  • 3.4.8 Belgium
  • 3.4.9 Switzerland
  • 3.4.10 Norway
  • 3.4.11 Denmark
  • 3.4.12 Sweden
  • 3.4.13 Finland
  • 3.4.14 Germany
  • 3.4.15 Czech Republic
  • 3.4.16 Russia Federation
  • 3.4.17 Poland
  • 3.4.18 Austria
  • 3.4.19 Romania
  • 3.4.20 Slovakia
  • 3.4.21 Greece
  • 3.4.22 Turkey
  • 3.4.23 Ukraine
• 3.5 Asia-Pacific
  • 3.5.1 Australia
  • 3.5.2 Japan
  • 3.5.3 Malaysia
  • 3.5.4 China
  • 3.5.5 India
  • 3.5.6 Thailand
  • 3.5.7 South Korea
• 3.6 Rest-of-the-World

4 Markets - Competitive Benchmarking

• 4.1 Key Strategies and Developments
• 4.2 Key Companies Ecosystem

5 Research Methodology

• 5.1 Data Sources
  • 5.1.1 Primary Data Sources
  • 5.1.2 Secondary Data Sources
  • 5.1.3 Data Triangulation
• 5.2 Market Estimation and Forecast

List of Figures

• Figure 1: Global Wound Biologics Market, $Million, 2022, 2026, and 2030
• Figure 2: Global Wound Biologics Market (by Region), $Million, 2022, 2026, and 2033
• Figure 3: Global Wound Biologics Market (by Product), $Million, 2022, 2026, and 2033
• Figure 4: Key Strategies Adopted by Market Players, 2021-2024
• Figure 5: Key Market Trends in Global Wound Biologics Market, 2023
• Figure 6: Strategic Initiatives, 2021-2024
• Figure 7: Share of Strategic Initiatives, 2021-2024
• Figure 8: Data Triangulation
• Figure 9: Top-Down and Bottom-Up Approach
• Figure 10: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Global Wound Biologics Market, Opportunities
• Table 3: Global Wound Biologics Market (by Product), $Million, 2021-2030
• Table 4: Global Wound Biologics Market (by Region), $Million, 2021-2030
• Table 5: North America Wound Biologics Market (by Product), $Million, 2021-2030
• Table 6: U.S. Wound Biologics Market (by Product), $Million, 2021-2030
• Table 7: Canada Wound Biologics Market (by Product), $Million, 2021-2030
• Table 8: Latin America Wound Biologics Market (by Product), $Million, 2021-2030
• Table 9: Argentina Wound Biologics Market (by Product), $Million, 2021-2030
• Table 10: Brazil Wound Biologics Market (by Product), $Million, 2021-2030
• Table 11: Chile Wound Biologics Market (by Product), $Million, 2021-2030
• Table 12: Colombia Wound Biologics Market (by Product), $Million, 2021-2030
• Table 13: Mexico Wound Biologics Market (by Product), $Million, 2021-2030
• Table 14: Europe Wound Biologics Market (by Product), $Million, 2021-2030
• Table 15: France Wound Biologics Market (by Product), $Million, 2021-2030
• Table 16: U.K. Wound Biologics Market (by Product), $Million, 2021-2030
• Table 17: Spain Wound Biologics Market (by Product), $Million, 2021-2030
• Table 18: Italy Wound Biologics Market (by Product), $Million, 2021-2030
• Table 19: Portugal Wound Biologics Market (by Product), $Million, 2021-2030
• Table 20: Netherlands Wound Biologics Market (by Product), $Million, 2021-2030
• Table 21: Ireland Wound Biologics Market (by Product), $Million, 2021-2030
• Table 22: Belgium Wound Biologics Market (by Product), $Million, 2021-2030
• Table 23: Switzerland Wound Biologics Market (by Product), $Million, 2021-2030
• Table 24: Norway Wound Biologics Market (by Product), $Million, 2021-2030
• Table 25: Denmark Wound Biologics Market (by Product), $Million, 2021-2030
• Table 26: Sweden Wound Biologics Market (by Product), $Million, 2021-2030
• Table 27: Finland Wound Biologics Market (by Product), $Million, 2021-2030
• Table 28: Germany Wound Biologics Market (by Product), $Million, 2021-2030
• Table 29: Czech Republic Wound Biologics Market (by Product), $Million, 2021-2030
• Table 30: Russia Federation Wound Biologics Market (by Product), $Million, 2021-2030
• Table 31: Poland Wound Biologics Market (by Product), $Million, 2021-2030
• Table 32: Austria Wound Biologics Market (by Product), $Million, 2021-2030
• Table 33: Romania Wound Biologics Market (by Product), $Million, 2021-2030
• Table 34: Slovakia Wound Biologics Market (by Product), $Million, 2021-2030
• Table 35: Greece Wound Biologics Market (by Product), $Million, 2021-2030
• Table 36: Turkey Wound Biologics Market (by Product), $Million, 2021-2030
• Table 37: Ukraine Wound Biologics Market (by Product), $Million, 2021-2030
• Table 38: Asia-Pacific Wound Biologics Market (by Product), $Million, 2021-2030
• Table 39: Australia Wound Biologics Market (by Product), $Million, 2021-2030
• Table 40: Japan Wound Biologics Market (by Product), $Million, 2021-2030
• Table 41: Malaysia Wound Biologics Market (by Product), $Million, 2021-2030
• Table 42: China Wound Biologics Market (by Product), $Million, 2021-2030
• Table 43: India Wound Biologics Market (by Product), $Million, 2021-2030
• Table 44: Thailand Wound Biologics Market (by Product), $Million, 2021-2030
• Table 45: South Korea Wound Biologics Market (by Product), $Million, 2021-2030
• Table 46: Rest-of-the-World Wound Biologics Market (by Product), $Million, 2021-2030
• Table 47: Key Companies, Global Wound Biologics Market